Organon (MEX:OGN) Institutional Ownership : 51.02% (As of Apr. 17, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Organon Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Organon's institutional ownership is 51.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Organon's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Organon's Float Percentage Of Total Shares Outstanding is 74.97%.

Organon Institutional Ownership Historical Data

The historical data trend for Organon's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon Institutional Ownership Chart

Organon Historical Data

The historical data trend for Organon can be seen below:

	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31
Institutional Ownership	53.06	53.24	53.38	52.72	52.87	52.93	56.10	55.75	55.48	51.02

Organon Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Organon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (MEX:OGN) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

OGN:USA 1OGN:Italy 0A9W:UK 7XP:Germany

Address

30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302

Website

https://www.organon.com

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.